DrugPatentWatch Database Preview
Drugs in Development Information for MEDI4736
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug MEDI4736?
MEDI4736 is an investigational drug.
There have been 249 clinical trials for MEDI4736.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 6th 2019.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).
There are twenty-one US patents protecting this investigational drug and seven hundred and sixty-five international patents.
Summary for MEDI4736
| US Patents | 21 |
| International Patents | 765 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-09-06) |
| Vendors | 0 |
Recent Clinical Trials for MEDI4736
| Title | Sponsor | Phase |
|---|---|---|
| DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | AstraZeneca | Phase 3 |
| DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | Australasian Lung Cancer Trials Group | Phase 3 |
| DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | PrECOG, LLC. | Phase 3 |
Clinical Trial Summary for MEDI4736
Top disease conditions for MEDI4736
Top clinical trial sponsors for MEDI4736
US Patents for MEDI4736
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MEDI4736 | Start Trial | Synergistic combination of immunologic inhibitors for the treatment of cancer | The University of Chicago (Chicago, IL) | Start Trial |
| MEDI4736 | Start Trial | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy | MedImmune Limited (Cambridge, GB) | Start Trial |
| MEDI4736 | Start Trial | Heterocyclic modulators of lipid synthesis | 3-V Biosciences, Inc. (Menlo Park, CA) | Start Trial |
| MEDI4736 | Start Trial | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | AstraZeneca AB (Sodertalje, SE) | Start Trial |
| MEDI4736 | Start Trial | Apilimod for use in the treatment of renal cancer | LAM Therapeutics, Inc. (Guilford, CT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MEDI4736
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MEDI4736 | Canada | 2889182 | 2032-10-26 | Start Trial |
| MEDI4736 | European Patent Office | 2911669 | 2032-10-26 | Start Trial |
| MEDI4736 | World Intellectual Property Organization (WIPO) | 2014066834 | 2032-10-26 | Start Trial |
| MEDI4736 | Australia | 2015276173 | 2034-06-17 | Start Trial |
| MEDI4736 | Brazil | 112016028964 | 2034-06-17 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
